OpGen (NASDAQ:OPGN) Now Covered by StockNews.com

StockNews.com began coverage on shares of OpGen (NASDAQ:OPGN) in a research note issued to investors on Friday. The firm issued a sell rating on the medical research company’s stock.

OpGen Stock Down 1.6 %

NASDAQ:OPGN opened at $1.23 on Friday. The company has a 50-day moving average of $1.02 and a 200-day moving average of $1.55. OpGen has a 52 week low of $0.53 and a 52 week high of $9.90.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.